Package Leaflet: Information for the User
EMEND 125mg hard capsules
EMEND 80mg hard capsules
aprepitant
Read all of this leaflet carefully before you or your child start taking this medicine, because it contains important information for you.If you are the parent of a child who is taking EMEND, read this information carefully.
Contents of the pack
EMEND contains the active substance aprepitant and belongs to a group of medicines called "neurokinin 1 (NK1) receptor antagonists". The brain has a specific area that controls nausea and vomiting. EMEND works by blocking the signals to this area, and thus reducing nausea and vomiting. EMEND hard capsules are used in adults and adolescents from 12 years of age, in combinationwith other medicinesto prevent nausea and vomiting caused by a type of chemotherapy (cancer treatment) that induces strong and moderate nausea and vomiting (such as cisplatin, cyclophosphamide, doxorubicin, or epirubicin).
Do not take EMEND
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you or your child start taking EMEND.
Before treatment with EMEND, tell your doctor if you or your child have liver disease, because the liver is important for removing the medicine from the body. Therefore, your doctor may need to monitor your liver or your child's liver.
Children and adolescents
Do not give EMEND 80 mg and 125 mg hard capsules to children under 12 years of age, because the 80 mg and 125 mg hard capsules have not been studied in this population.
Other medicines and EMEND
EMEND may affect other medicines during and after treatment with EMEND. There are some medicines that should not be taken with EMEND (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment (see also ‘Do not take EMEND’).
The effects of EMEND or other medicines may be influenced if you or your child take EMEND with other medicines, including those listed below. Talk to your doctor or pharmacist if you or your child are taking any of the following medicines:
Tell your doctor or pharmacist if you or your child are taking, have recently taken, or might take any other medicines.
Pregnancy and breastfeeding
Do not use this medicine during pregnancy unless clearly necessary. If you or your child are pregnant or breastfeeding, or think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
For information on birth control, see ‘Other medicines and EMEND’.
It is not known if EMEND passes into breast milk; therefore, breastfeeding should be avoided during treatment with this medicine. It is important to tell your doctor before taking this medicine if you or your child are breastfeeding or plan to breastfeed.
Driving and using machines
It should be taken into account that some people have dizziness and drowsiness after taking EMEND. If you or your child feel dizzy or drowsy, avoid driving, cycling, or using machines or tools after taking this medicine (see ‘Possible side effects’).
EMEND contains sucrose
EMEND hard capsules contain sucrose. If your doctor has told you or your child that you have an intolerance to some sugars, talk to your doctor before taking this medicine.
EMEND contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per hard capsule; this is essentially “sodium-free”.
Always take this medicine exactly as your doctor, pharmacist, or nurse has told you or your child. If you are not sure, talk to your doctor, pharmacist, or nurse. Take EMEND with other medicines to prevent nausea and vomiting. After treatment with EMEND, your doctor may ask you or your child to continue taking other medicines to prevent nausea and vomiting, including corticosteroids (such as dexamethasone) and a ‘5-HT3 antagonist’ (such as ondansetron). If you are unsure, talk to your doctor, pharmacist, or nurse.
The recommended oral dose of EMEND is:
Day 1:
and
Days 2 and 3:
EMEND can be taken with or without food.
Swallow the capsule whole with some liquid.
If you take more EMEND than you should
Do not take more capsules than your doctor recommends. If you or your child have taken too many capsules, contact your doctor immediately.
If you forget to take EMEND
If you or your child have missed a dose, ask your doctor for advice.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking EMEND and contact your doctor immediately if you or your child notice any of the following serious side effects, for which you or your child may need urgent medical treatment:
Other side effects that have been reported are listed below.
Common side effects(may affect up to 1 in 10 people) are:
Uncommon side effects(may affect up to 1 in 100 people) are:
Rare side effects(may affect up to 1 in 1,000 people) are:
Reporting of side effects
If you or your child experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
Store in the original package to protect from moisture.
Do not remove the capsule from the blister until you are ready to take it.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of EMEND
Appearance and packaging
The 125 mg hard capsule is opaque with a white body and pink cap with “462” and “125 mg” printed in radial form in black ink on the body.
The 80 mg hard capsule is opaque with a white body and white cap with “461” and “80 mg” printed in radial form in black ink on the body.
EMEND 125 mg and 80 mg hard capsules are supplied in the following pack sizes:
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem Netherlands |
For further information on this medicine, contact the local representative of the marketing authorization holder:
Belgium MSD Belgium Tel: +32 (0)2 776 6211 dpoc_belux@msd.com | Lithuania UAB Merck Sharp & Dohme Tel: +370 5 278 0247 dpoc_lithuania@msd.com |
Luxembourg MSD Belgium Tel: +32 (0)2 776 6211 dpoc_belux@msd.com | |
Czech Republic Merck Sharp & Dohme, s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com | Hungary MSD Pharma Hungary Kft. Tel: +36 1 888 5300 hungary_msd@merck.com |
Denmark MSD Danmark ApS Tel: +45 4482 4000 dkmail@msd.com | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com |
Germany MSD Sharp & Dohme GmbH Tel: +49 (0)89 20 300 4500 medinfo@msd.de | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) medicalinfo.nl@merck.com |
Estonia Merck Sharp & Dohme OÜ Tel: +372 614 4200 dpoc.estonia@msd.com | Norway MSD (Norge) AS Tel: +47 32 20 73 00 medinfo.norway@msd.com |
Greece MSD Α.Φ.Ε.Ε. Tel: +30 210 98 97 300 dpoc_greece@merck.com | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0)1 26 044 dpoc_austria@merck.com |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@msd.com | Poland MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com |
France MSD France Tel: +33 (0)1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com |
Croatia Merck Sharp & Dohme d.o.o. Tel: +385 1 6611 333 croatia_info@merck.com | Romania Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@msd.com | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 520 4201 msd_slovenia@merck.com |
Iceland Vistor ehf. Tel: +354 535 7000 | Slovakia Merck Sharp & Dohme, s.r.o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com |
Italy MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) dpoc.italy@msd.com | Finland MSD Finland Oy Tel: +358 (0)9 804 650 info@msd.fi |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 800 00 673 (+357 22866700) cyprus_info@merck.com | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@msd.com |
Latvia SIA Merck Sharp & Dohme Latvija Tel: +371 67025300 dpoc.latvia@msd.com |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu.